A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
about
Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis.Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in ChinaItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter StudyNeuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification.Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.Review article: the investigation and management of gastric neuroendocrine tumours.AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas.Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome.Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumorsCorrelation of Ki-67 indices from biopsy and resection specimens of neuroendocrine tumours.Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs.Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors.The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.Clinical presentation in insulinoma predicts histopathological tumour characteristics.Insulinoma Presenting with Reactive Hypoglycemia: Evaluating the Effect of Tumor Resection via Continuous Glucose Monitoring.Predictive Factors for Lymph Node Metastasis and Prognostic Factors for Survival in Rectal Neuroendocrine Tumors.Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates.PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment.Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours.Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors?Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors.
P2860
Q28078610-1229DEAF-6503-4E96-9616-772E1B450489Q30252003-413501B8-4F64-4231-9155-CBA61A74864FQ33684746-A5391403-D8B1-4111-BE94-AFAADDB3F9EBQ34157385-89897A8E-ED38-4FB1-882A-EC7FF086D761Q35565766-A43A5E5E-BA81-4606-9000-FF7703BA365EQ36344419-20C3DEA9-1207-4D53-A09B-B06E77CF14D7Q37206218-531C5BFA-06E7-4C8E-83DB-2CE4AE557AF2Q37373285-710EC388-71A9-4BF4-959F-D14F0D04045AQ37520405-89585B05-F4A2-44CB-97D7-212525DD265AQ37631597-72AA3C90-9F88-4171-90BD-DC4D72BD3BC3Q38195905-4EF3B659-A25A-4893-B13D-47D453FF5FF0Q38472691-637D924D-E7D5-4C3E-954A-E46643B702D1Q38777613-1D24DFDB-139F-4B66-A1CB-FD25B1A599ABQ38958626-3880ED1E-ACAF-42F5-AB73-9CCDB45D4F7FQ39022631-F9602187-5E52-4789-A168-50B6FBDD544FQ39524711-BAC28E0F-F941-4224-92DB-74E7E2F03416Q40094521-0674964F-1A6C-4365-A135-C27FD6281EB8Q40288265-ED92AA5E-E070-4353-A60B-C0A8A24819C0Q40874923-38DA93D3-098D-4CC2-B617-8AFC6A4A21CDQ41148371-E2073FF6-3D68-48FE-B1E7-B62A0E45F52AQ47123654-DF77951B-022F-47C7-9F99-15B9EAE3B29DQ47765091-B36B3242-C085-43B9-8EBD-5BEFF20FC997Q48120130-AF7FB94D-D083-4025-A535-21BC958C1CA4Q50086050-DC9B99DF-F569-4A31-A786-D8F4CBF93F77Q50136080-1F3F8BA0-3E62-4F48-B5B6-21B2B1B8DB51Q50863966-57B93923-09FF-4012-84D2-6A70A521E379Q55078460-1FECF7FE-6856-4D09-821E-92238919462C
P2860
A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A comparison of Ki-67 and mito ...... idgut neuroendocrine neoplasms
@en
type
label
A comparison of Ki-67 and mito ...... idgut neuroendocrine neoplasms
@en
prefLabel
A comparison of Ki-67 and mito ...... idgut neuroendocrine neoplasms
@en
P2093
P2860
P356
P1476
A comparison of Ki-67 and mito ...... idgut neuroendocrine neoplasms
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2013.156
P407
P577
2013-04-11T00:00:00Z